What's in Shortage

The generic drug Heparin Sodium Injection, also known by brand names HEPARIN SODIUM and HEPARIN SODIUM IN SODIUM CHLORIDE, is in a current shortage status. It is an injection with a therapeutic category in hematology. The shortage was first posted on 11/14/2017 and last updated on 04/02/2026.

Which Manufacturers Are Affected

• Fresenius Kabi USA, LLC: Available for presentations Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77) and Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10). Related info: Check wholesalers for inventory. Contact info: 888-386-1300.
• Hospira, Inc., a Pfizer Company: Available for presentations Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59) and Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03). Contact info: 844-646-4398.
• Baxter Healthcare: Available for presentation Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03). Unavailable for presentation Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0424-18) due to product discontinuation. Contact info: 888-229-0001.

Why There's a Shortage

No specific reason was provided in the source data for this shortage.

What Patients Should Do

Patients experiencing issues with obtaining Heparin Sodium Injection should talk to their pharmacist about availability and options. They may also contact the relevant manufacturer using the provided contact information. Remember, patients should consult their healthcare provider for any guidance on their treatment; this article does not provide medical advice.

Source

Information from the FDA Drug Shortage Database.